瑞加诺生负荷快速磁共振心肌灌注病例1例

Fast Magnetic Resonance Myocardial Perfusion Imaging with Regadenoson: A Case Report and Review of the Literature

摘要: 近年来，磁共振心肌灌注成像已成为心肌存活性和心肌血流量评估的重要无创检查手段。心肌灌注可分为静息和负荷两种，相较于静息心肌灌注，负荷心肌灌注可提高检测准确性，并提供微循环功能障碍的诊断信息。临床常用的负荷药物为腺苷，需在磁共振扫查期间利用抗磁输液泵持续泵注，这增加了成本和技术难度。瑞加诺生是一种有效的选择性A_2A腺苷受体激动剂，可实现弹丸式给药且作用时间可人为控制，为更简便、更快速的负荷磁共振心肌灌注带来了新可能。本文报道了我院于2022年5月开展的国内首例应用瑞加诺生的快速磁共振负荷心肌灌注检查。

Abstract: In recent years, cardiac magnetic resonance perfusion imaging has become an important non-invasive diagnostic tool for the combined assessment of myocardial perfusion, myocardial viability, and myocardial function. Myocardial perfusion can be categorized into resting and stress states. Compared to resting myocardial perfusion, stress myocardial perfusion, by increasing the metabolic demand of the myocardium, can improve the positive detection rate of reduced myocardial perfusion and accurately detect coronary artery disease at an early stage. However, the commonly used stress agent adenosine has a very short half-life, requiring continuous infusion during the examination, which not only increases cost but also raises technical difficulty. Regadenoson is an effective selective A_2A adenosine receptor agonist that can be administered as a bolus and prolongs the duration of action, offering significantly better results than adenosine and bringing new possibilities to stress cardiac magnetic resonance perfusion imaging. This article reports on the first case in China in May 2022 where regadenoson was used for rapid magnetic resonance stress myocardial perfusion examination conducted at our hospital.